To meet growing demand for its global services LOG, a pharma primary packaging specialist specialising in oxygen and moisture barrier solutions, is significantly expanding its manufacturing floor to increase capacity.
The expansion includes the construction of a new multi-million-dollar ISO Class 8 cleanroom that will bring significant productivity benefits to its blue-chip customers across the world, including Unilever, Teva, Chemo and Gedeon Richter.
This major investment in new facilities provides corporate cutting-edge automated online inspection and Artificial Intelligence (AI) surveillance. The expansion also ensures immediate and reliable detection of defects to provide the highest level of product quality control and consistency for customers which, in the UK, are served by a European Sales Office based in Switzerland.
The 600 sqm expansion of its packaging site at its Israel HQ has been designed with state-of-the-art capabilities
The factory floor expansion is currently underway and on schedule for completion by August 2022 and will underpin LOG's sustainable provision of 24/7 production facilities.
LOG has developed a series of world-leading barrier packaging solutions to extend the shelf life and protect innovative and generic drugs from the exposure to moisture and/or oxygen. Made from up to six layers, LOG's barrier packaging solutions are available for liquids and solids, and come in standard sizes from 15 to 1500ml and with neck finishes between SP20 and SP53.&
The 600 sqm expansion of its packaging site at its Israel HQ has been designed with state-of-the-art capabilities, enabling LOG to boost production of its highly innovative and sustainable solutions. The cleanroom project also showcases a commitment to meet and exceed customer expectations and emphasises LOG's position at the forefront of innovation and as a leading pharma primary packaging solution provider.
Shaul Bassi, LOG's CEO says the company, which also has a manufacturing site in Hungary, is seeing rapid growth for its class-leading packaging solutions for pharmaceutical companies worldwide. The latest expansion is part of the company's strategy to create new opportunities in the highly-competitive pharma primary packaging market.
Bassi explained: "We're excited to announce the significant expansion of our manufacturing facilities. As a leading pharmaceutical packaging company, this is the right time to boost our production capability and underpin our future growth. This will enable us to increase our ground-breaking pharma packaging solutions as we maximise our cutting-edge production technology."
LOG's pharma packaging solutions are manufactured using a range of blow moulding technology, including extrusion blow moulding (EBM), injection blow moulding (IBM), injection stretch blow moulding (ISBM) and CoEx-EBM. LOG also leverages injection and other technologies, as well as providing designated printing areas, desiccant filling and assembly services. Most of LOG's pharma primary packaging solutions are listed in the US FDA's Drug Master File (DMF).
